BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:BSX • US1011371077
77.2 EUR
-1.8 (-2.28%)
Last: Feb 3, 2026, 07:00 PM
Taking everything into account, BSX scores 6 out of 10 in our fundamental rating. BSX was compared to 68 industry peers in the Health Care Equipment & Supplies industry. BSX has an excellent profitability rating, but there are some minor concerns on its financial health. BSX shows excellent growth, but is valued quite expensive already. With these ratings, BSX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
- In the past year BSX was profitable.
- In the past year BSX had a positive cash flow from operations.
- Of the past 5 years BSX 4 years were profitable.
- Each year in the past 5 years BSX had a positive operating cash flow.
1.2 Ratios
- BSX has a better Return On Assets (6.54%) than 75.00% of its industry peers.
- With a decent Return On Equity value of 11.93%, BSX is doing good in the industry, outperforming 72.06% of the companies in the same industry.
- BSX has a better Return On Invested Capital (8.09%) than 70.59% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BSX is below the industry average of 9.62%.
- The 3 year average ROIC (6.59%) for BSX is below the current ROIC(8.09%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROIC | 8.09% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
1.3 Margins
- BSX has a Profit Margin of 14.42%. This is amongst the best in the industry. BSX outperforms 83.82% of its industry peers.
- In the last couple of years the Profit Margin of BSX has declined.
- BSX's Operating Margin of 19.40% is amongst the best of the industry. BSX outperforms 82.35% of its industry peers.
- In the last couple of years the Operating Margin of BSX has remained more or less at the same level.
- BSX's Gross Margin of 68.57% is fine compared to the rest of the industry. BSX outperforms 77.94% of its industry peers.
- BSX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% |
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BSX is destroying value.
- BSX has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for BSX has been increased compared to 5 years ago.
- Compared to 1 year ago, BSX has a worse debt to assets ratio.
2.2 Solvency
- BSX has an Altman-Z score of 5.18. This indicates that BSX is financially healthy and has little risk of bankruptcy at the moment.
- BSX has a better Altman-Z score (5.18) than 83.82% of its industry peers.
- The Debt to FCF ratio of BSX is 3.03, which is a good value as it means it would take BSX, 3.03 years of fcf income to pay off all of its debts.
- With a decent Debt to FCF ratio value of 3.03, BSX is doing good in the industry, outperforming 75.00% of the companies in the same industry.
- A Debt/Equity ratio of 0.48 indicates that BSX is not too dependend on debt financing.
- The Debt to Equity ratio of BSX (0.48) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 5.18 |
ROIC/WACC0.82
WACC9.91%
2.3 Liquidity
- BSX has a Current Ratio of 1.51. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.51, BSX is in line with its industry, outperforming 45.59% of the companies in the same industry.
- BSX has a Quick Ratio of 1.51. This is a bad value and indicates that BSX is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Quick ratio value of 0.96, BSX perfoms like the industry average, outperforming 41.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
- BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.00%, which is quite impressive.
- Measured over the past years, BSX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.56% on average per year.
- The Revenue has grown by 21.62% in the past year. This is a very strong growth!
- BSX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.30% yearly.
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
3.2 Future
- The Earnings Per Share is expected to grow by 15.06% on average over the next years. This is quite good.
- The Revenue is expected to grow by 12.60% on average over the next years. This is quite good.
EPS Next Y22.12%
EPS Next 2Y18.13%
EPS Next 3Y16.37%
EPS Next 5Y15.06%
Revenue Next Year20.92%
Revenue Next 2Y16.08%
Revenue Next 3Y14.31%
Revenue Next 5Y12.6%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 30.88 indicates a quite expensive valuation of BSX.
- The rest of the industry has a similar Price/Earnings ratio as BSX.
- BSX is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 28.18, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 26.01, which means the current valuation is very expensive for BSX.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of BSX is on the same level as its industry peers.
- BSX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 25.51.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.88 | ||
| Fwd PE | 26.01 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BSX is valued a bit more expensive than the industry average as 66.18% of the companies are valued more cheaply.
- BSX's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.33 | ||
| EV/EBITDA | 28.48 |
4.3 Compensation for Growth
- BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- BSX has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as BSX's earnings are expected to grow with 16.37% in the coming years.
PEG (NY)1.4
PEG (5Y)3.23
EPS Next 2Y18.13%
EPS Next 3Y16.37%
5. Dividend
5.1 Amount
- BSX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:BSX (2/3/2026, 7:00:00 PM)
77.2
-1.8 (-2.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-22 2025-10-22/bmo
Earnings (Next)02-04 2026-02-04/bmo
Inst Owners94.07%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap114.44B
Revenue(TTM)19.35B
Net Income(TTM)2.79B
Analysts85.5
Price Target108.94 (41.11%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)-0.14%
PT rev (3m)-1.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.01%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)1.76%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)0.13%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.88 | ||
| Fwd PE | 26.01 | ||
| P/S | 6.98 | ||
| P/FCF | 35.33 | ||
| P/OCF | 29.2 | ||
| P/B | 5.77 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.48 |
EPS(TTM)2.5
EY3.24%
EPS(NY)2.97
Fwd EY3.84%
FCF(TTM)2.19
FCFY2.83%
OCF(TTM)2.64
OCFY3.42%
SpS11.06
BVpS13.37
TBVpS-1.13
PEG (NY)1.4
PEG (5Y)3.23
Graham Number27.43
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROCE | 10.04% | ||
| ROIC | 8.09% | ||
| ROICexc | 8.38% | ||
| ROICexgc | 28.19% | ||
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% | ||
| FCFM | 19.76% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
ROICexc(3y)6.75%
ROICexc(5y)5.93%
ROICexgc(3y)22.84%
ROICexgc(5y)19.53%
ROCE(3y)8.18%
ROCE(5y)7.08%
ROICexgc growth 3Y9.18%
ROICexgc growth 5Y7.17%
ROICexc growth 3Y4.96%
ROICexc growth 5Y5.6%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.18 | ||
| Cap/Depr | 59.36% | ||
| Cap/Sales | 4.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.6% | ||
| Profit Quality | 136.98% | ||
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 5.18 |
F-Score6
WACC9.91%
ROIC/WACC0.82
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
EPS Next Y22.12%
EPS Next 2Y18.13%
EPS Next 3Y16.37%
EPS Next 5Y15.06%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
Revenue Next Year20.92%
Revenue Next 2Y16.08%
Revenue Next 3Y14.31%
Revenue Next 5Y12.6%
EBIT growth 1Y30.66%
EBIT growth 3Y13.12%
EBIT growth 5Y10.92%
EBIT Next Year37.52%
EBIT Next 3Y20.65%
EBIT Next 5Y17.42%
FCF growth 1Y125.15%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y96.47%
OCF growth 3Y22.44%
OCF growth 5Y13.34%
BOSTON SCIENTIFIC CORP / BSX.DE FAQ
What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE.
What is the valuation status for BSX stock?
ChartMill assigns a valuation rating of 3 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Overvalued.
How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?
BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 7 / 10.
What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 30.88 and the Price/Book (PB) ratio is 5.77.
Can you provide the expected EPS growth for BSX stock?
The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 22.12% in the next year.